Should I Take MOTS-c? Start With These Questions

Should I take MOTS-c? The evidence in people is too thin to make it a routine choice for weight loss or tiredness. Alex is a fictional composite: 48, tired most afternoons, and training for local road races. Alex takes metformin for prediabetes, blood sugar above normal but below the diabetes range.

For Alex, a visit is about the tiredness, blood sugar and training together. A provider would work through these questions before deciding whether MOTS-c fits.

1. Should I take MOTS-c for a specific goal?

MOTS-c is a peptide, a short chain of 16 protein building blocks. Its code comes from mitochondria, the cell's energy-making parts. Researchers study its effects on AMPK, an energy-sensing switch inside cells.

The 2015 discovery paper in Cell Metabolism reported prevention of diet-related obesity in mice. That cannot give Alex a human weight-loss target. Who discovered MOTS-c explains the finding behind the interest.

Alex's weight and afternoon tiredness are separate questions. A provider first asks about the tiredness, sleep, training and current care. If you have a specific concern rather than a general wish for more energy, raise it at your visit.

2. Does the MOTS-c evidence match what you expect?

The human exercise finding often gets mistaken for a treatment result. In a 2021 Nature Communications study, 10 healthy young men cycled while researchers measured the MOTS-c their bodies made. They weren't given MOTS-c. The treatment experiments were in mice; MOTS-c and exercise separates those findings.

CohBar tested CB4211, an analogue, meaning a modified relative of MOTS-c. Its phase 1 trial, an early study mainly checking safety, enrolled 88 people overall. The company's August 10, 2021 report described a four-week analysis of 20 adults with obesity and fatty liver. Weight findings were a trend. A different molecule's early results don't establish what the original MOTS-c peptide will do for Alex.

As of September 30, 2026, the day this article was written, MOTS-MET's registry record, last updated April 1, lists 120 planned participants and no results. This separate trial tests MOTS-c against placebo, a dummy injection, in adults with prediabetes and overweight or obesity.

If you need a predictable amount of weight loss or a proven workout benefit, this probably isn't for you.

3. Are your races covered by anti-doping rules?

A local race doesn't tell a provider which rules apply. Alex's competition status belongs in the conversation, even if racing is a hobby.

The World Anti-Doping Agency, or WADA, names MOTS-c in its 2026 list. It sits under S4.4.1, AMPK activators, substances that turn on that energy-sensing switch. It's prohibited at all times, during and outside competition.

As of September 30, 2026, the day this article was written, WADA's 2027 list keeps that listing. WADA published it September 21, 2026, and it takes effect January 1, 2027.

A prescription alone doesn't exempt an athlete from those rules. If you compete under WADA rules, this probably isn't for you.

4. Who should not take MOTS-c without a longer discussion?

Alex's metformin matters. The MOTS-MET trial excludes recent use of medicines that lower blood sugar, including metformin. Even when it reports, it won't directly answer whether adding MOTS-c to Alex's medication helps or creates problems.

The trial also excludes pregnancy, breastfeeding, planned pregnancy, active cancer requiring treatment, significant liver disease and reduced kidney function. Known allergy to peptide medicines or formulation ingredients is another exclusion. These are gaps in who the study can speak for, rather than proof that each condition causes harm with MOTS-c.

FDA's May 11, 2026 briefing found insufficient human safety information to describe the risks. It raised concerns about immunogenicity, an immune response against the peptide, including possible effects of impurities or clumping. MOTS-c side effects explains the uncertainties.

If you are pregnant, breastfeeding or planning pregnancy, this probably isn't for you right now. If you take medicines or have a relevant health history, raise it at your visit.

5. Did the July compounding recommendation settle the decision?

As of September 30, 2026, the day this article was written, the July 23 committee recommendation is advice about compounding. FDA's official recording shows recommendations to add MOTS-c to the 503A bulks list, an ingredient list for certain compounding. Compounding means a pharmacy prepares medication for a particular patient. FDA isn't required to follow the committee's advice.

That recommendation didn't establish a weight-loss benefit or approve a medicine. The September MOTS-c update covers the wider regulatory picture.

Through Promise, MOTS-c is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. MOTS-c has never had a U.S.-approved drug product. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

If the headline is what made you interested, the next question is whether the evidence fits your goal: raise it at your visit.

6. Would NAD+ better match the question you're asking?

If Alex's main concern is feeling worn out, the conversation may turn to NAD+. It's a molecule cells use in energy reactions, rather than a peptide signal like MOTS-c. That biology doesn't establish that treatment will make someone feel more energetic.

One practical question is format. Promise offers NAD+ as a compounded injectable only — 100 mg/mL × 10 mL vial (1,000 mg) — by prescription, after a licensed provider reviews your request. A preference about needles can help frame the conversation, but doesn't establish which treatment works better or is safer.

NAD+ is a separate treatment question. Alex wouldn't get an answer about it from the MOTS-c studies, and adding both wouldn't resolve the evidence gap.

If you're asking about an alternative for energy, raise it at your visit.

7. What would make a visit useful for Alex?

The useful starting point is Alex's medication list, recent blood-sugar results, training schedule and description of the tiredness. A provider can discuss whether the existing care needs attention before considering something else.

If MOTS-c remains part of that discussion, the plan needs more than a start date. What specific change would count as helpful? How would it be measured? When would the decision be reviewed, and who would handle a possible side effect?

A prescription provides a clinical relationship and pharmacy accountability. It doesn't supply the missing trial results. Alex may hear that a different treatment fits better, that more evaluation comes first, or that the uncertainty outweighs the reason to try it.

At Promise, a licensed provider reviews every request, and not everyone qualifies.

If you can name the problem and are ready to discuss the evidence, your medicines and the follow-up plan, raise it at your visit.